The Dermatological Drugs Market: 2024 – 2034 - Opportunities, Challenges, Strategies & Forecasts​

Release Date: September 2024
Number of Pages: 325
Number of Tables and Figures: 50
Companies Profiles: 82
Pipeline Candidates: 236

For Enquiries, Press, Sample Pages and Table of Contents please contact: [email protected]
​
Synopsis: The global dermatological drugs market is experiencing rapid growth, driven by an increasing prevalence of skin disorders and a rising demand for innovative therapies. Companies are actively expanding their portfolios to address diverse dermatological conditions, capitalizing on unmet medical needs and the push for more targeted, high-efficacy treatments. This strategic shift is reshaping the industry landscape, with breakthroughs in biologics, biosimilars, and novel therapies for conditions like psoriasis, atopic dermatitis, and skin cancer, positioning the sector for robust expansion in 2024 and beyond.

Although surgery and other therapies are widely used for the treatment of certain skin conditions, dermatological drugs continue to account for the highest percentage of spending within the wider market for dermatology products.

Expected to reach nearly $45 Billion in global spending by the end of 2024, dermatological drugs remain the preferred approach to treat common skin disorders, ranging from acne to more complicated conditions such as psoriasis. Despite the loss of patent protection for several blockbuster drugs which has attracted generic competition, the market is ripe for future growth with several novel drugs in late-stage development.
Within this evolving landscape, biologics have emerged as a game-changer, particularly for chronic skin conditions like psoriasis, atopic dermatitis, and alopecia areata. These therapies, often derived from living cells, offer targeted treatment options with improved efficacy, providing new hope for patients who have not responded well to traditional treatments.

Simultaneously, advancements in drug delivery systems, especially in topical formulations, are playing a crucial role in market growth. Innovative delivery platforms such as microneedle technology, are enhancing the penetration of active ingredients into the skin while minimizing side effects and improving tolerability, even on compromised skin. 

The “Dermatological Drugs Market: 2024 – 2034 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the dermatological drugs ecosystem including dermatological disorders, application areas, delivery technologies, key trends, market drivers, challenges, investment potential, leading therapies, drug development pipeline, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for dermatological drugs from 2024 through to 2034. The forecasts are segmented for over 7 therapeutic categories, 5 regions and 26 leading countries.

The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report and 2024 clinical pipeline dataset.
For a Sample and Table of Contents please contact [email protected]

Pricing: The report is available for the following price: 
​
Single User License: USD 3,000

Company Wide License (Single Site): USD 4,500

Company Wide License (Global Site): USD 7,500

Key Findings:
The report has the following key findings:​
  • Expected to reach nearly $45 Billion in global spending by the end of 2024, dermatological drugs remain the preferred approach to treat common skin disorders, ranging from Acne to more complicated conditions such as Psoriasis.
  • Biologics continue to dominate the dermatological drugs market, with recent major approvals driving growth. Notable approvals include Adbry (tralokinumab) for atopic dermatitis, Dupixent (dupilumab) expanded indications for chronic spontaneous urticaria and prurigo nodularis, and Bimzelx (bimekizumab) for plaque psoriasis in Europe. 
  • Novel biologics such as Dupilumab (targeting IL-4 and IL-13) continue to dominate the market for atopic dermatitis, while newer therapies like Bimekizumab, which targets both IL-17A and IL-17F, are emerging as key treatments for psoriasis.
  • These approvals highlight the industry's focus on innovative biologic therapies addressing a broader range of chronic skin conditions, solidifying their market foothold.
  • New drug development programs for psoriasis and atopic dermatitis in 2024 are focused on targeting selective interleukins, including IL-4, IL-13, IL-17, IL-23, and IL-31, with several recent advancements. 
  • IL-23 inhibitors like Risankizumab and Guselkumab are gaining traction as they offer improved safety profiles and durable efficacy compared to earlier therapies. These interleukin inhibitors represent a growing trend toward more targeted and effective therapies, addressing both moderate to severe cases and offering long-term control. 
  • Other programs include but are not limited to PD-L1 (Programmed Death Ligand-1) antibodies; topical treatments such as JAK (Janus Kinase) inhibitors, TYIs (Tyrosine Kinase Inhibitors) and PDE-4 (Phosphodiesterase-4) inhibitors; MEK and BRAF  inhibitors; and new classes of antibiotics.
  • The market is continuing to consolidate with several prominent acquisitions and partnerships such as the recent acquisition of U.S. based Proteologix by J&J. This acquisition is crucial for dermatology, as it includes two pre-clinical bispecific antibodies, PX-128 and PX-130, targeting pathways in atopic dermatitis. 

Topics Covered:
The report covers the following topics:
  • Dermatological drugs ecosystem
  • Market drivers and barriers
  • Dermatological disorders, application areas and key trends
  • Analysis of key drug classes and leading dermatological drugs
  • Future drug development pipeline
  • Dermatological drug delivery technologies
  • Industry roadmap and value chain
  • Profiles and strategies of 82 leading ecosystem players, including dermatological drug developers
  • Strategic recommendations for ecosystem players
  • Market analysis and forecasts from 2024 till 2034

Forecast Segmentation:
Market forecasts are provided for each of the following submarkets and their subcategories:
  • Therapeutic Category
    • Acne & Rosacea
    • Alopecia & Hair Disorders
    • Dermatitis
    • Psoriasis
    • Skin Infections
    • Skin Cancer
    • Other Conditions
  • Regional Markets
    • ​Asia Pacific
    • Europe
    • Middle East & Africa
    • North America
    • Latin & Central America
  • Country Markets
    • Australia
    • ​Brazil
    • Canada
    • China
    • Egypt
    • France
    • Germany
    • Greece
    • India
    • Israel
    • Italy
    • Japan
    • Mexico
    • Netherlands
    • Poland
    • Portugal
    • Russia
    • Saudi Arabia
    • South Africa
    • South Korea
    • Spain
    • Switzerland
    • Taiwan
    • Turkey
    • UK
    • USA

Key Questions Answered:
The report provides answers to the following key questions:
  • How big is the dermatological drugs opportunity?
  • What trends, challenges and barriers are influencing its growth?
  • How is the ecosystem evolving by segment and region?
  • What will the market size be in 2024 and at what rate will it grow?
  • Which countries and submarkets will see the highest percentage of growth?
  • What are the prospects of biosimilar drugs in dermatology?
  • What are the key drug delivery technologies being used in dermatological treatments?
  • How big is the market for Psoriasis drugs?
  • Who are the key market players and what are their strategies?
  • How will patent expirations of innovator drugs impact the market?
  • What strategies should dermatological drug manufacturers adopt to remain competitive? 

List of Companies Mentioned:
The following companies and organizations have been reviewed, discussed or mentioned in the report:
AB Science
Abbott Laboratories
AbbVie
Abeona Therapeutics
AbGenomics
AbGenomics International
Aclaris Therapeutics
Actelion Pharmaceuticals
Adgero Biopharmaceuticals
AiCuris
Akros Pharma
Alder Biopharmaceuticals
Alexion
Allakos
Allergan
Almirall
Amgen
Amryt Pharma
Anacor Pharmaceuticals
AnaptysBio
AndroScience Corporation
Angimmune
AOBiome
Apexigen
ApoPharma
Apotex
Aralez Pharmaceuticals
Arbor Pharmaceuticals
Arcutis
arGentis Pharmaceuticals
Array BioPharma
Arrevus
Asana BioSciences
Assertio Therapeutics
Astellas Pharma
AstraZeneca
Athenex
Atox Bio
Autotelic Bio
Basilea Pharmaceutica
Bausch Health Companies
Bayer
Beijing Wenfeng Tianji Pharmaceuticals
Berg Pharma
BioAlliance Pharma 
Biocon
Biofrontera
Biogen
BioMimetix
Bioniz
BioPharmX Corporation
Biotest
Biothera
Birken GmbH
BMS (Bristol-Myers Squibb)
Boehringer Ingelheim
Botanix Pharmaceuticals
Brickell Biotech
Cadila Pharmaceuticals
Cambridge Antibody Technology
Can-Fite BioPharma
Cara Therapeutics
Cassiopea
Castle Creek Pharma
Celgene Corporation
Celltrion Healthcare
Celtaxsys
Cerbios-Pharma
Chugai Pharmaceutical
Cipher Pharmaceuticals
Clinuvel Pharmaceuticals
Coherus BioSciences
Concert Pharmaceuticals
Corbus Pharmaceuticals
Creabilis SA
Croma Pharma
Cumberland Pharmaceuticals
Cutanea Life Sciences
Cytori 
Debiopharm
Dermata Therapeutics
Dermavant Sciences
Dermira
Dr. Reddy's Laboratories
DS Biopharma
Eirion Therapeutics
Eisai
Eli Lilly
Elios Therapeutics
Elorac
EMA (European Medicines Agency)
EMD Serono
Encore Dermatology
EPI Health
Escalier Biosciences
European Commission
Evelo Biosciences
Exelixis
Exicure
FAES Farma
Fibrocell Science
Foamix
Forward Pharma
Fresenius Kabi
G&E Herbal Biotechnology
Galapagos
Galderma
Galectin Therapeutics
Genentech
Gilead Sciences
Glenmark Pharmaceuticals
GSK (GlaxoSmithKline)
Hallux
Hapten Sciences
HedgePath Pharmaceuticals
Histogen Inc
Horizon Pharma
Hospira
Hoth Therapeutics
Hovione
Hugel
Huya Bioscience
iCo Therapeutics
Idera Pharmaceuticals
Immune Pharmaceuticals
Immunocore
Incyte Corporation
InflaRx
Innovation Pharmaceuticals
Intrexon Corporation
Iovance Biotherapeutics
Janssen Biotech
Jiangsu Hengrui Medicine
Johnson & Johnson
JT (Japan Tobacco)
Kadmon Holdings
Kiniksa Pharmaceuticals
Krystal Biotech
Kythera Biopharmaceuticals
LEO Pharma
Lipidor
Lycera
Maruho Company
Mateon Therapeutics
Mayne Pharma Group
Meda Pharmaceuticals
Medimetriks Pharmaceuticals
MedImmune
Medivir
Melinta Therapeutics
Menlo Therapeutics
Merck & Co.
Merck KGaA
MicuRx Pharmaceuticals
miRagen Therapeutics
Moberg Pharma
Momenta Pharmaceuticals
MorphoSys
Motif Bio
Mycovia Pharmaceuticals
Mylan
N&N Pharmaceuticals
Nabriva Therapeutics
Nanology
NantKwest
Nektar
Neumedicines
NewLink Genetics
Nielson BioSciences
NovaBiotics
Novan
Novartis
Novella Clinical
Nowarta Biopharma
Octapharma
Oncolys Biopharma
Oncosec Medical
Oncotelic
Ono Pharmaceutical Company
Onxeo
Ortho Dermatologics
Paratek Pharmaceuticals
Patagonia Pharmaceuticals
PellePharm
Pfizer
PharmaDerm
Philogen
Phio Pharmaceuticals
Photocure
Photogen Technologies Inc.
Pierre Fabre (Laboratoires Pierre Fabre)
Pola Pharma
Poli Group
Polichem
PolyMedix
Polynoma
Portola Pharmaceuticals
Principia Biopharma
Promius Pharma
ProQR Therapeutics
Provectus Biopharmaceuticals
Purdue Pharma
Quotient Sciences
Qurient
Ralexar Therapeutics
Realm Therapeutics
Reata Pharmaceuticals
Regeneron Pharmaceuticals
Revance Therapeutics
Roche
Roche Holding (F. Hoffmann-La Roche)
Roivant Sciences
R-Pharm
Samsung Bioepis
Samsung BioLogics
Samsung Group
Samumed
Sandoz
Sanofi
Santalis Healthcare
Sienna Biopharmaceuticals
Signum Biosciences
Sinclair Pharma
Sirbal
Sol-Gel Technologies
Soligenix
Stiefel Laboratories
Sun Pharma (Sun Pharmaceutical Industries)
Sun Pharmaceutical 
Syndax Pharmaceuticals
Takara Bio
Takeda Pharmaceutical Company
Tanox
Taro Pharmaceutical
Teva Pharmaceutical Industries
The Medicines Company
Theravance Biopharma
ThermiGen
Tioga Pharmaceuticals
Topotarget
Torii Pharmaceutical Company
Trevi Therapeutics
U.S. FDA (Food and Drug Administration)
UCB
Valeant Pharmaceuticals
Vanda Pharmaceuticals
Vectans Pharma
Veloce BioPharma
Verrica Pharamceuticals
VidacPharma
VielaBio
Viralytics
Vitae Pharmaceuticals
Vitaeris
XBiotech
XenoPort
Ziarco
Zydus Group (Cadila Healthcare)